MSOP
目录号 : GC17185MSOP 是一种选择性 III 族代谢型谷氨酸受体拮抗剂，对 L-AP4 敏感的突触前 mGluR 的表观 KD 为 51 μM。
Cas No.:66515-29-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats[2]Male Sprague-Dawley rats (250-300 g) are housed individually in cages on a standard 12 h-12 h light-dark cycle. Water and food are available as libitum until rats are transported to the labotatory approximately 1 h before the experiments. A glutamate transporter activator, three glutamate transporter inhibitors, TBOA, DL-THA, dihydrokainate, and a selective group III mGluR antagonist MSOP are used. All drugs are dissolved in 0.9% physiological saline. To examine the role of group III mGluRs in the antinociceptive effect produced by intrathecal TBOA in the formalin model, the rats are intrathecally injected with saline (10 μL; n=5), MSOP (10 μg/10 μL; n=5), TBOA (10 μg/10 μL; n=5), or MSOP plus TBOA (n=5). Ten minutes later, 2% formalin (100 μL) is injected into the plantar side of a hind paw and formalin-induced pain behaviors are assessed.To examine the role of group III mGluRs in the antinociceptive effect produced by intrathecal TBOA in the complete Freund’s adjuvant (CFA) model, the rats are intrathecally injected with saline (10 μL; n=5), MSOP (10 μg/10 μL; n=5), TBOA (10 μg/10 μL; n=5), or MSOP plus TBOA (n=5) at 6 h post-CFA and then measured paw withdrawal latencies[2]. |
References: [1]. Thomas NK, et al. alpha-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists. Neuropharmacology. 1996 Jun;35(6):637-42. | |
MSOP is a selective group III metabotropic glutamate receptor antagonist with apparent KD of 51 μM for the L-AP4-sensitive presynaptic mGluR.
In the presence of 200 μM MSOP, a rightward parallel shift of the dose-response curve to L-AP4 is observed, with an apparent KD calculated as 51±6 μM (n=3). MSOP is shown to be selective for the L-APC sensitive presynaptic mGluR, the apparent KD for the interaction of MSOP with the (1S, 3S)-ACPD sensitive receptor calculated as greater than 700 μM (n=3)[1].
It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model: F3,16=30.96, P<0.001; CFA model: F3,16=30.77, P<0.001). As expected, intrathecal TBOA (10 μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01). The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group. CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group[2].
References:
[1]. Thomas NK, et al. alpha-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists. Neuropharmacology. 1996 Jun;35(6):637-42.
[2]. Myron Yaster, et al. Effect of inhibition of spinal cord glutamate transporters on inflammatory pain induced by formalin and complete Freund’s adjuvant. Anesthesiology. 2011 Feb; 114(2): 412–423.
| Cas No. | 66515-29-5 | SDF | |
| 化学名 | (R)-2-amino-2-methyl-3-(phosphonooxy)propanoic acid | ||
| Canonical SMILES | OC([C@](COP(O)(O)=O)(C)N)=O | ||
| 分子式 | C4H10NO6P | 分子量 | 199.1 |
| 溶解度 | <19.91mg/ml in Water | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.0226 mL | 25.113 mL | 50.226 mL |
| 5 mM | 1.0045 mL | 5.0226 mL | 10.0452 mL |
| 10 mM | 0.5023 mL | 2.5113 mL | 5.0226 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。